B7-H6 (human):Fc (mouse) (rec.)

CHF 420.00
In stock
CHI-HF-211B7H6-C100100 µgCHF 420.00
More Information
Product Details
Product Type Protein
Properties
Source/Host HEK 293 cells
Sequence

The extracellular domain of human B7-H6 (aa 25-262) is fused to the N-terminus of the Fc region of mouse IgG2a.

Crossreactivity Human
MW ~80kDa (SDS-PAGE)
Purity ≥98% (SDS-PAGE)
Endotoxin Content <5EU/mg protein (LAL test; Lonza).
Reconstitution Reconstitute with 100 µl sterile water.
Add 1X PBS to the desired protein concentration.
Formulation Lyophilized from 0.2μm-filtered solution in PBS.
Protein Negative Control

Fc (mouse) IgG2a Control (rec.)

Other Product Data

NCBI reference NP_001189368.1: B7-H6 (human)

Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

B7-H6 is a glycosylated member of the B7 family of immune costimulatory proteins. Orthologs in mouse and rat have not been identified. The Ig-like V domain mediates 1:1 stoichiometric binding of B7-H6 to NKp30 expressed on NK cells. It does not show binding to NKp44, NKp46, or NKG2D. Ligation of NKp30 by B7-H6 induces NK cell activation and target cell cytolysis. B7-H6 is expressed on a wide range of hematopoietic, carcinoma, and melanoma tumor cells, which is consistent with the detection of NKp30 binding sites on many tumors. The expression of NKp30 ligands on tumor cells correlates with tumor cell sensitivity to NKp30-dependent cell lysis.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.